Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

Business Wire

Wed, Aug 27, 2025, 4:57 PM 23 min read

TEANECK, N.J., August 27, 2025--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026.

Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024)

• Net sales of $378.7 million, an increase of $105.5 million, or 39%

• Net income of $17.2 million, an increase of $16.5 million

• Diluted earnings per share of $0.42, an increase of $0.40

• Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49%

• Adjusted net income of $23.2 million, an increase of $6.6 million, or 39%

• Adjusted diluted EPS of $0.57, an increase of $0.16, or 39%

Highlights for the year ended June 30, 2025 (compared to the year ended June 30, 2024)

• Net sales of $1,296.2 million, an increase of $278.5 million, or 27%

• Net income of $48.3 million, an increase of $45.8 million

• Diluted earnings per share of $1.19, an increase of $1.13

• Adjusted EBITDA of $183.7 million, an increase of $72.4 million, or 65%

• Adjusted net income of $84.9 million, an increase of $36.6 million, or 76%

• Adjusted diluted EPS of $2.09, an increase of $0.90, or 76%

We are providing full fiscal year 2026 guidance, which includes:

• Net sales of $1.43 billion to $1.48 billion

• Adjusted EBITDA of $225 million to $235 million

COMMENTARY

"Phibro delivered exceptional fourth-quarter and full-year results, reflecting the strength and balance of our Animal Health portfolio," stated Jack Bendheim, President and Chief Executive Officer. "We achieved 27% growth in annual net sales and a 65% increase in adjusted EBITDA, driven by sustained demand across MFAs, nutritional specialties, and vaccines. Our legacy Animal Health business continued to grow, while the Zoetis MFA portfolio exceeded expectations, contributing to a 54% year-over-year increase in MFA and Other product sales."

"These results underscore the successful execution of our Phibro Forward initiatives, which are unlocking efficiencies and driving sustainable growth. Higher SG&A reflects deliberate investments in scaling our operations to support our expanding global footprint and innovation pipeline. Despite these investments, we grew adjusted net income by 76% for the year."

"Looking ahead, our FY 2026 guidance reflects continued confidence in our trajectory, supported by the strength of our portfolio, disciplined execution, and momentum across all segments. We remain focused on driving sustainable growth and creating long-term value for our customers and shareholders."